Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
26-28 August, 2025
Not Confirmed
Not Confirmed
12-14 August, 2025
Not Confirmed
Not Confirmed
17-21 August, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
26-28 August, 2025
Industry Trade Show
Not Confirmed
12-14 August, 2025
Industry Trade Show
Not Confirmed
17-21 August, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint
31 Jul 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/07/31/3124761/0/en/ImmuneOnco-Announced-Preliminary-Safety-Efficacy-Data-from-the-Clinical-Trial-Studying-IMM2510-AXN-2510-a-PD-L1xVEGF-Bispecific-Antibody-in-Combination-with-Chemotherapy-in-Front-l.html
31 Jul 2025
// FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/instils-licensed-pd-l1xvegf-bispecific-shows-promise-china-instilling-hope-upcoming-us-test
02 Jul 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/07/02/3109003/0/en/Instil-Bio-Announces-U-S-F-D-A-Clearance-of-Investigational-New-Drug-IND-Application-for-AXN-2510-a-PD-L1xVEGF-Bispecific-Antibody-for-a-Phase-1-Trial-in-Relapsed-Refractory-Solid-.html
23 May 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/05/23/3087397/0/en/Instil-Bio-and-ImmuneOnco-to-Host-Investor-and-Analyst-Breakfast-to-Discuss-the-Evolving-PD-L-1xVEGF-Bispecific-Antibody-Landscape-and-Clinical-Trial-Updates-During-the-2025-ASCO-A.html
22 May 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/05/22/3086415/0/en/Instil-Bio-and-ImmuneOnco-Announced-the-Phase-2-Trial-in-First-line-NSCLC-of-IMM2510-AXN-2510-2510-a-PD-L1xVEGF-Bispecific-Antibody-in-Combination-with-Chemotherapy-in-China-is-on-.html
14 Jan 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/01/14/3009179/0/en/Instil-Bio-Announces-Clinical-Progress-in-China-for-IMM2510-SYN-2510-a-Clinical-Stage-PD-L1xVEGF-Bispecific-Antibody.html
ABOUT THIS PAGE